Molecular simulation studies on the binding activity and selectivity of 3-amino-phenyl-5-chloro-pyrimidine-2, 4-diamine derivatives in complexes with kinases c-Met and ALK

References

• Rankin EB, Giaccia AJ. The receptor tyrosine kinase AXL in cancer progression. Cancers (Basel). 2016;8:103. doi: 10.3390/cancers8110103
   Web of Science ®Google Scholar
• Hsu JL, Hung M-C. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metast Rev. 2016;35:575–588. doi: 10.1007/s10555-016-9649-6
   PubMed Web of Science ®Google Scholar
• Aguilera TA, Giaccia AJ. Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion – a new role for the AXL receptor tyrosine kinase. Clin Cancer Res. 2017;23:2928–2933. doi: 10.1158/1078-0432.CCR-17-0189
   PubMed Web of Science ®Google Scholar
• Miekus K. The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance (review). Oncol Rep. 2017;37:647–656. doi: 10.3892/or.2016.5297
   PubMed Web of Science ®Google Scholar
• Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1–26. doi: 10.1016/j.canlet.2004.09.044
   PubMed Web of Science ®Google Scholar
• Lv P-C, Wang Z-C, Zhu H-L. Recent advances in the design and synthesis of c-Met inhibitors as anticancer agents (2014-present). Curr Med Chem. 2017;24:57–64. doi: 10.2174/0929867323666161028161441
   PubMed Web of Science ®Google Scholar
• Holla VR, Elamin YY, Bailey AM, et al. ALK: a tyrosine kinase target for cancer therapy. Mol Case Studies. 2017;3:a001115. doi: 10.1101/mcs.a001115
   Google Scholar
• Hallberg B, Palmer R. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27:iii4–iii15. doi: 10.1093/annonc/mdw301
   PubMedGoogle Scholar
• Wiesner T, Lee W, Obenauf AC, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015;526:453–457. doi: 10.1038/nature15258
   PubMed Web of Science ®Google Scholar
• Siraj AK, Beg S, Jehan Z, et al. ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res. 2015;17:1–12. doi: 10.1186/s13058-015-0610-3
   PubMed Web of Science ®Google Scholar
• Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 1995;376:768–771. doi: 10.1038/376768a0
   PubMed Web of Science ®Google Scholar
• D’Amico L, Belisario D, Migliardi G, et al. C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. Oncotarget. 2016;7:45525–45537. doi: 10.18632/oncotarget.9997
   PubMedGoogle Scholar
• Jia H, Dai G, Weng J, et al. Discovery of (S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for trea. J Med Chem. 2014;57:7577–7589. doi: 10.1021/jm500510f
   PubMed Web of Science ®Google Scholar
• Bellon SF, Kaplan-Lefko P, Yang Y, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008;283:2675–2683. doi: 10.1074/jbc.M705774200
   PubMed Web of Science ®Google Scholar
• Iyevleva AG, Raskin GA, Tiurin VI, et al. Novel ALK fusion partners in lung cancer. Cancer Lett. 2015;362:116–121. doi: 10.1016/j.canlet.2015.03.028
   PubMed Web of Science ®Google Scholar
• Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metast Rev. 2003;22:309–325. doi: 10.1023/A:1023768811842
   PubMed Web of Science ®Google Scholar
• Burudpakdee C, et al. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. Lung Cancer. 2018;119:103–111. doi: 10.1016/j.lungcan.2018.03.008
   PubMed Web of Science ®Google Scholar
• Stoica GE, Wong W, Seetasith A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001;276:16772–16779. doi: 10.1074/jbc.M010660200
   PubMed Web of Science ®Google Scholar
• Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277:35990–35998. doi: 10.1074/jbc.M205749200
   PubMed Web of Science ®Google Scholar
• Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7:137–155. doi: 10.1158/2159-8290.CD-16-1123
   PubMed Web of Science ®Google Scholar
• Yao S, Cheng M, Zhang Q, et al. Anaplastic lymphoma kinase is required for neurogenesis in the developing central nervous system of zebrafish. PLOS One. 2013;8:e63757. doi: 10.1371/journal.pone.0063757
   PubMed Web of Science ®Google Scholar
• Gunby R, Ahmed S, Sottocornola R, et al. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J Med Chem. 2006;49:5759–5768. doi: 10.1021/jm060380k
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371:2167–2177. doi: 10.1056/NEJMoa1408440
   PubMed Web of Science ®Google Scholar
• Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci. 2011;108:7535–7540. doi: 10.1073/pnas.1019559108
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Azada M, Dy J, et al. Asymptomatic profound sinus bradycardia (heart rate≤45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol. 2011;6:2135–2137. doi: 10.1097/JTO.0b013e3182307e06
   PubMed Web of Science ®Google Scholar
• Ou SHI, Tong WP, Azada M, et al. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer. 2013;119:1969–1975. doi: 10.1002/cncr.28040
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–1019. doi: 10.1016/S1470-2045(12)70344-3
   PubMed Web of Science ®Google Scholar
• Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005;10:139–147. doi: 10.1016/S1359-6446(04)03316-1
   PubMed Web of Science ®Google Scholar
• Taylor RD, Jewsbury PJ, Essex JW. A review of protein-small molecule docking methods. J Comput Aided Mol Des. 2002;16:151–166. doi: 10.1023/A:1020155510718
   PubMed Web of Science ®Google Scholar
• Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010–2011 in review. J Mol Recog. 2013;26:215–239. doi: 10.1002/jmr.2266
   PubMed Web of Science ®Google Scholar
• Pujadas G, Vaque M, Ardevol A, et al. Protein-ligand docking: a review of recent advances and future perspectives. Curr Pharm Anal. 2008;4:1–19. doi: 10.2174/157341208783497597
   Web of Science ®Google Scholar
• Varela L, Méndez-Morales T, Carrete J, et al. Solvation of molecular cosolvents and inorganic salts in ionic liquids: a review of molecular dynamics simulations. J Mol Liq. 2015;210:178–188. doi: 10.1016/j.molliq.2015.06.036
   Web of Science ®Google Scholar
• Ganesan A, Coote ML, Barakat K. Molecular dynamics-driven drug discovery: leaping forward with confidence. Drug Discov Today. 2017;22:249–269. doi: 10.1016/j.drudis.2016.11.001
   PubMed Web of Science ®Google Scholar
• Peddi SR, Sivan SK, Manga V. Molecular dynamics and MM/GBSA-integrated protocol probing the correlation between biological activities and binding free energies of HIV-1 TAR RNA inhibitors. J Biomol Struct Dyn. 2017;36:1–18.
   Web of Science ®Google Scholar
• Song Z, Yang Y, Liu Z, et al. Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases. J Med Chem. 2015;58:197–211. doi: 10.1021/jm5005144
   PubMed Web of Science ®Google Scholar
• D’Angelo ND, Bellon SF, Booker SK, et al. Design, synthesis, and biological evaluation of potent c-Met inhibitors. J Med Chem. 2008;51:5766–5779. doi: 10.1021/jm8006189
   PubMedGoogle Scholar
• Huang WS, Liu S, Zou D, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem. 2016;59:4948. doi: 10.1021/acs.jmedchem.6b00306
   PubMed Web of Science ®Google Scholar
• Leardi R. Genetic algorithms in chemometrics and chemistry: a review. J Chemom. 2001;15:559–569. doi: 10.1002/cem.651
   Web of Science ®Google Scholar
• Cruciani G, Watson KA. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J Med Chem. 1994;37:2589–2601. doi: 10.1021/jm00042a012
   PubMed Web of Science ®Google Scholar
• Ho CMW, Marshall GR. Cavity search: an algorithm for the isolation and display of cavity-like binding regions. J Comput Aided Mol Des. 1990;4:337–354. doi: 10.1007/BF00117400
   PubMed Web of Science ®Google Scholar
• Case DA, Babin V, Berryman JT, et al. Amber 14. Mech Eng. 2014;126:14–20.
   Google Scholar
• Norberto DSO, Ornstein RL. Effect of warmup protocol and sampling time on convergence of molecular dynamics simulations of a DNA dodecamer using AMBER 4.1 and particle-mesh Ewald method. J Biomol Struct Dyn. 1997;14:607–611. doi: 10.1080/07391102.1997.10508160
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Chandrasekhar J, Madura JD, et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926–935. doi: 10.1063/1.445869
   Web of Science ®Google Scholar
• Chohan TA, Qian H-Y, Pan Y-L, et al. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7. Mol Biosyst. 2016;12:145–161. doi: 10.1039/C5MB00630A
   PubMedGoogle Scholar
• Salomon-Ferrer R, Götz AW, Poole D, et al. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. explicit solvent particle mesh Ewald. J Chem Theory Comput. 2013;9:3878–3888. doi: 10.1021/ct400314y
   PubMed Web of Science ®Google Scholar
• Roe DR, Cheatham III TE. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9:3084–3095. doi: 10.1021/ct400341p
   PubMed Web of Science ®Google Scholar
• Roweis S, Ghahramani Z. A unifying review of linear Gaussian models. Neural Comput. 1999;11:305–345. doi: 10.1162/089976699300016674
   PubMed Web of Science ®Google Scholar
• Afshari HH, Gadsden SA, Habibi SR. Gaussian filters for parameter and state estimation: a general review of theory and recent trends. Signal Process. 2017;135:218–238. doi: 10.1016/j.sigpro.2017.01.001
   Web of Science ®Google Scholar
• Jayathilaka PB, Pathiraja GC, Bandara A, et al. Theoretical study of phenol and hydroxyl radical reaction mechanism in aqueous medium by the DFT/B3LYP/6-31+ G (d, p)/CPCM model. Can J Chem. 2014;92:809–813. doi: 10.1139/cjc-2014-0191
   Web of Science ®Google Scholar
• Ni R, Mitsuda N, Kashiwagi T, et al. Heteroatom-embedded medium-sized cycloalkynes: concise synthesis, structural analysis, and reactions. Angew Chem Int Ed. 2015;54:1190–1194. doi: 10.1002/anie.201409910
   PubMed Web of Science ®Google Scholar
• Chohan TA, Chen J-J, Qian H-Y, et al. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations. Mol Biosyst. 2016;12:1250–1268. doi: 10.1039/C5MB00860C
   PubMedGoogle Scholar
• Woon DE, Dunning TH Jr. Gaussian basis sets for use in correlated molecular calculations. V. Core-valence basis sets for boron through neon. J Chem Phys. 1995;103:4572–4585. doi: 10.1063/1.470645
   Web of Science ®Google Scholar
• Subroto T, Nuwarda RF, Baroroh U, et al. In silico study of cryo-EM structures of antigen-antibody complex of chikungunya for the development of diagnostic agent. Asian J Pharm Clin Res. 2017;10:62. doi: 10.22159/ajpcr.2017.v10s2.19489
   Google Scholar
• Cui JJ, Tran-Dubé M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54:6342–6363. doi: 10.1021/jm2007613
   PubMed Web of Science ®Google Scholar